Outlook Therapeutics Inc (OTLK)

$1.57 +0.10 (6.80%)
Market Cap 65.30M
Revenue (ttm) 0.00
Net Income (ttm) -75.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.38
Volume 7,828,900
Avg Vol 2,935,942
Day's Range N/A - N/A
Shares Out 44.42M
Stochastic %K 63%
Beta 0.60
Analysts Sell
Price Target $6.80

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
GenerallyGentle
GenerallyGentle Nov. 15 at 1:23 PM
$OTLK My job is to read charts and this weekly candle is SICK !!!!! I LOVE IT !!! It closed above the last weekly (10/13) selling wick/pivot (1.54). Plus higher pivot low (1.13). powerful, very powerful. More to come ... much much more. We are climbing out of the pits of hell and getting ready to enter heaven !!! Have a great weekend everyone. God Bless !!!!
1 · Reply
Consti22
Consti22 Nov. 15 at 11:03 AM
$OTLK 💪🙏
0 · Reply
Consti22
Consti22 Nov. 15 at 11:02 AM
$OTLK Hey friends. What do you think the price would be if it were approved? I think between $6 and $8 would be realistic. 😎💪🍀 extrem>>>
2 · Reply
baboonandbanana
baboonandbanana Nov. 15 at 5:36 AM
$OTLK damnit i cant wait for december alr
0 · Reply
xxtpat
xxtpat Nov. 15 at 4:22 AM
$OTLK Sold some of my $CDTX yesterday. Increased my position of $OTLK to 91K
1 · Reply
SteelerJon
SteelerJon Nov. 15 at 3:18 AM
$OTLK Always! 😎🏦🏦
0 · Reply
Britbox
Britbox Nov. 15 at 2:56 AM
$OTLK
2 · Reply
RNASequencing
RNASequencing Nov. 15 at 2:04 AM
$OTLK broke as hell. As long as not ugly raise prior to pdufa they can likely raise at higher less dilutionary pricing. Let’s hope management does the right thing and takes out a line of credit to keep the lights on.
1 · Reply
superOTLK
superOTLK Nov. 15 at 1:17 AM
$OTLK Bid: $1.54 X 500 Ask: $1.66 X 181 Volume: 7,852,378 Look the excitement in the activity !
0 · Reply
superOTLK
superOTLK Nov. 15 at 1:12 AM
$OTLK
0 · Reply
Latest News on OTLK
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 13, 2025, 8:30 AM EST - 2 days ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Nov 3, 2025, 8:35 AM EST - 12 days ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 6 weeks ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 3, 2025, 8:35 AM EDT - 2 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 2 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:51 AM EDT - 2 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 2 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:39 AM EDT - 2 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Aug 28, 2025, 6:30 AM EDT - 2 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 24, 2025, 9:15 AM EDT - 2 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 8:05 AM EDT - 3 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 24, 2025, 9:00 AM EDT - 4 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 8:05 AM EDT - 4 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 18, 2025, 9:05 AM EDT - 5 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 10, 2025, 8:05 AM EDT - 5 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 23, 2025, 6:30 AM EDT - 6 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 22, 2025, 4:01 PM EDT - 6 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 6 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Apr 8, 2025, 8:45 AM EDT - 7 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 8:05 AM EST - 9 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 9 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:05 AM EST - 9 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 4, 2025, 9:05 AM EST - 10 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 8:05 AM EST - 10 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 23, 2025, 9:05 AM EST - 10 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 9:05 AM EST - 10 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 10 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 16, 2025, 6:00 AM EST - 10 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Top 3 Health Care Stocks That Could Blast Off This Month

Jan 6, 2025, 7:19 AM EST - 11 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 27, 2024, 8:05 AM EST - 11 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 9:27 AM EST - 1 year ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 27, 2024, 6:50 AM EST - 1 year ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 4, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 12:02 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 14, 2024, 7:05 AM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 12, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Aug 7, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 9:10 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

GenerallyGentle
GenerallyGentle Nov. 15 at 1:23 PM
$OTLK My job is to read charts and this weekly candle is SICK !!!!! I LOVE IT !!! It closed above the last weekly (10/13) selling wick/pivot (1.54). Plus higher pivot low (1.13). powerful, very powerful. More to come ... much much more. We are climbing out of the pits of hell and getting ready to enter heaven !!! Have a great weekend everyone. God Bless !!!!
1 · Reply
Consti22
Consti22 Nov. 15 at 11:03 AM
$OTLK 💪🙏
0 · Reply
Consti22
Consti22 Nov. 15 at 11:02 AM
$OTLK Hey friends. What do you think the price would be if it were approved? I think between $6 and $8 would be realistic. 😎💪🍀 extrem>>>
2 · Reply
baboonandbanana
baboonandbanana Nov. 15 at 5:36 AM
$OTLK damnit i cant wait for december alr
0 · Reply
xxtpat
xxtpat Nov. 15 at 4:22 AM
$OTLK Sold some of my $CDTX yesterday. Increased my position of $OTLK to 91K
1 · Reply
SteelerJon
SteelerJon Nov. 15 at 3:18 AM
$OTLK Always! 😎🏦🏦
0 · Reply
Britbox
Britbox Nov. 15 at 2:56 AM
$OTLK
2 · Reply
RNASequencing
RNASequencing Nov. 15 at 2:04 AM
$OTLK broke as hell. As long as not ugly raise prior to pdufa they can likely raise at higher less dilutionary pricing. Let’s hope management does the right thing and takes out a line of credit to keep the lights on.
1 · Reply
superOTLK
superOTLK Nov. 15 at 1:17 AM
$OTLK Bid: $1.54 X 500 Ask: $1.66 X 181 Volume: 7,852,378 Look the excitement in the activity !
0 · Reply
superOTLK
superOTLK Nov. 15 at 1:12 AM
$OTLK
0 · Reply
NxtBgThng
NxtBgThng Nov. 14 at 11:28 PM
$OTLK Great week... Been a long slog here but feeling like it's going to be worth it in the end
0 · Reply
Joker83
Joker83 Nov. 14 at 11:06 PM
$OTLK i have a feeling we will see a 3.30 by December
1 · Reply
Marusch
Marusch Nov. 14 at 9:04 PM
$OTLK Have a great weekend, everyone. We're doing everything right here!
1 · Reply
baboonandbanana
baboonandbanana Nov. 14 at 8:45 PM
$OTLK see yall on monday lads
0 · Reply
OldManLogan
OldManLogan Nov. 14 at 8:44 PM
$OTLK Average price to sales in biotech is somewhere between 6x and 12x... so slap a 9x on those numbers and compare to the current market cap... 😮
0 · Reply
lucinith
lucinith Nov. 14 at 8:04 PM
$OTLK added 3k more
0 · Reply
cntrade1
cntrade1 Nov. 14 at 7:58 PM
$OTLK
0 · Reply
Bgirl_smirk
Bgirl_smirk Nov. 14 at 7:39 PM
$OTLK every dip I add
0 · Reply
spacewolf1234
spacewolf1234 Nov. 14 at 7:36 PM
$OTLK
0 · Reply
CliffordCapital
CliffordCapital Nov. 14 at 7:21 PM
$OTLK I loaded today again. Will buy more next week!! Let‘s get to the pre CRL levels! 3$ next month!
0 · Reply
SteelerJon
SteelerJon Nov. 14 at 6:44 PM
$OTLK Why is this stuck on $1.56 for like the last hour?
11 · Reply
lucinith
lucinith Nov. 14 at 6:19 PM
$OTLK who ever is shorting right now, I hope you get burned to crisp next week when they announce approved and accepted application.
1 · Reply